Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Comment by MirrorWorldManon Jun 16, 2022 11:08am
229 Views
Post# 34761326

RE:RE:Nice bid this morning

RE:RE:Nice bid this morningThat last news release by Howie about Corporate changes moving forward is likely an attempt by Howie to inform the public that he thinks the deal is big, but cannot provide numbers.  It is his surrogate to deal details   Afterall, there is no real news at all in that release, just internal strategic managment plans that companies make everyday.  It is odd that Howie never releases detailed information about things that matter most, that policy will change quickly if we ever get uplisted to a decent exchange.  All payments and royalties are concisely communicated in every similar deal with BioTechs/Big Pharm I have invested on NASDAQ AMEX NYSE.  So crazy odd that Howie has not figured that out and pushed to have details published.  Its a significant as I hope now he sees
<< Previous
Bullboard Posts
Next >>